Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
Public ClinicalTrials.gov record NCT00413010. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD). Efficacy will be measured by the improvement in the total Hamilton Anxiety Rating Scale (HAM-A) scores from baseline observed following 8 weeks of double-blind treatment or at earlier termination during the double-blind treatment phase and analyzed using a mixed linear model for repeated measures.
Study identification
- NCT ID
- NCT00413010
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 356 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2006 (Type not available)
- Primary completion
- Feb 2008 (Actual)
- Completion
- Mar 2008 (Actual)
- Last update posted
- Feb 10, 2021
2006 – 2008
United States locations
- U.S. sites
- 35
- U.S. states
- 19
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Arcadia | California | 91007-3462 | — |
| Pfizer Investigational Site | Burbank | California | 91506 | — |
| Pfizer Investigational Site | Redlands | California | 92374 | — |
| Pfizer Investigational Site | Sherman Oaks | California | 91403 | — |
| Pfizer Investigational Site | Norwich | Connecticut | 06360 | — |
| Pfizer Investigational Site | Destin | Florida | 32541 | — |
| Pfizer Investigational Site | Fort Walton Beach | Florida | 32547 | — |
| Pfizer Investigational Site | Miami | Florida | 33143 | — |
| Pfizer Investigational Site | South Miami | Florida | 33143 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66212 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67207 | — |
| Pfizer Investigational Site | Shreveport | Louisiana | 71101 | — |
| Pfizer Investigational Site | Shreveport | Louisiana | 71104 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21208 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Olive Branch | Mississippi | 38654 | — |
| Pfizer Investigational Site | Saint Charles | Missouri | 63301 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68131 | — |
| Pfizer Investigational Site | Clementon | New Jersey | 08021 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Pfizer Investigational Site | New York | New York | 10128-1708 | — |
| Pfizer Investigational Site | Beachwood | Ohio | 44122 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45227 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44109-1998 | — |
| Pfizer Investigational Site | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Pfizer Investigational Site | Media | Pennsylvania | 19063 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19104-3309 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19136 | — |
| Pfizer Investigational Site | Columbia | South Carolina | 29201 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38117 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38133 | — |
| Pfizer Investigational Site | Houston | Texas | 77008 | — |
| Pfizer Investigational Site | Houston | Texas | 77074 | — |
| Pfizer Investigational Site | Lake Jackson | Texas | 77566 | — |
| Pfizer Investigational Site | Waukesha | Wisconsin | 53188-1660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00413010, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2021 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00413010 live on ClinicalTrials.gov.